Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Practical management of chronic lymphocytic leukemia with acalabrutinib

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse

Therapeutic Options for Relapsed/Refractory Mantle Cell Lymphoma

Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies

A Randomized Phase 3 Trial of Zanubrutinib versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: THE ASPEN STUDY

An International Multicenter Retrospective Analysis of Patients With Extranodal Marginal Zone Lymphoma and Histologically Confirmed Central Nervous System and Dural Involvement

Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL